Medicare will start covering weight-loss drugs on July 1 for the first time. Here’s what you need to know

A new Medicare pilot program starting July 1 will provide weight-loss drugs at $50 monthly to eligible enrollees with specific BMI and health criteria, marking the first Medicare coverage for these medications. The program covers Wegovy, Zepbound, and Foundayo but excludes those with type 2 diabetes or already receiving GLP-1 drugs through Medicare. It aims to improve health outcomes and is expected to be cost-neutral over 24 months, running through 2027.